

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Generic Name:	buprenorphine
Brand Name:	BuTrans
Strength:	5mcg/hr, 10mcg/hr and 20mcg/hr transdermal patch
Manufacturer:	Purdue Pharma
Indication:	Management of persistent pain of moderate intensity in adults requiring continuous opioid analgesia for an extended period of time
Rapid Review:	Not requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	10/12/2010	28/01/2011	EO decision rendered	Funding not available through Ontario Public Drug Programs
Second Review (Resubmission #1)	30/12/2011	12/01/2012	EO decision rendered	Funding not available through Ontario Public Drug Programs

Rapid Review:

Details of the Rapid Review process can be found at:

www.health.gov.on.ca/english/providers/program/drugs/drug_submissions/rapid_review_process.html

Review Status:

- Screening – Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.
- Executive Officer (EO) decision rendered.

Funding Decision:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision can be found at: www.health.gov.on.ca/english/providers/program/drugs/ced_rec_table.html

Updated: May 17, 2012